Fulcrum Therapeutics (FULC)

• Market cap: $852M
• 1 day: -0.62%
• 5 days: 1.57%
• 1 month: 33.89%
• 3 months: 82.74%
• 6 months: 90%
• Year to date: 166.94%
• 1 year: 192.31%
• 5 years: -3.58%
• 10 years: -4.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45